{"id":67428,"date":"2026-06-05T13:57:45","date_gmt":"2026-06-05T05:57:45","guid":{"rendered":"https:\/\/flcube.com\/?p=67428"},"modified":"2026-06-05T13:57:46","modified_gmt":"2026-06-05T05:57:46","slug":"sichuan-biokin-enrolls-first-patient-in-phase-iii-trial-of-bl-m05d1-adc-for-claudin18-2-positive-gastric-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67428","title":{"rendered":"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced the enrollment of the first patient in a <strong>Phase III clinical study<\/strong> evaluating <strong>BL-M05D1<\/strong>, an innovative <strong>antibody drug conjugate (ADC)<\/strong> targeting <strong>Claudin18.2<\/strong>, in patients with <strong>Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\/GEJC)<\/strong> who have received prior first-line therapy.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III (first subject enrolled)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Claudin18.2-positive advanced GC\/GEJC with prior first-line therapy<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Not disclosed (standard endpoints include progression-free survival and overall survival)<\/td><\/tr><tr><td><strong>Global Trial Portfolio<\/strong><\/td><td>Three active trials: Phase III, Phase Ib, Phase Ia<\/td><\/tr><tr><td><strong>Broader Indication<\/strong><\/td><td>Locally advanced solid tumors across all trials<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-technology-platform\" class=\"wp-block-heading\">Drug Profile &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> BL-M05D1 \u2013 <strong>Claudin18.2-targeting antibody drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Technology Heritage:<\/strong> Derived from same platform as Biokin&#8217;s <strong>BL-B01D1<\/strong><\/li>\n\n\n\n<li><strong>Platform Consistency:<\/strong> Shares identical <strong>&#8220;linker + toxin&#8221; platform<\/strong> with established predecessor<\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> <strong>Claudin18.2<\/strong> expressed in 30-40% of gastric cancers, representing substantial biomarker-defined population<\/li>\n\n\n\n<li><strong>Therapeutic Strategy:<\/strong> Precision oncology approach targeting specific molecular subset of difficult-to-treat gastrointestinal cancers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Gastric Cancer Treatment Landscape<\/th><th>BL-M05D1 Positioning<\/th><\/tr><\/thead><tbody><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Chemotherapy \u00b1 immunotherapy for second-line treatment<br>Limited effective options post-progression<\/td><\/tr><tr><td><strong>Competitive ADCs<\/strong><\/td><td>Zymeworks&#8217; zanidatamab (bispecific antibody)<br>Other Claudin18.2 programs in early development<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>China accounts for ~40% of global gastric cancer cases<br>Approximately 150,000 new GC\/GEJC cases annually in China alone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-biokin\" class=\"wp-block-heading\">Strategic Implications for Biokin<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Expands beyond BL-B01D1 into additional high-value oncology indications<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success would validate Biokin&#8217;s ADC platform across multiple tumor types and targets<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Leverages existing oncology commercial capabilities in China&#8217;s large gastric cancer market<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Phase III trial supports potential international regulatory filings and partnership opportunities<\/li>\n\n\n\n<li><strong>Investor Confidence:<\/strong> Progression to Phase III demonstrates de-risked development path and strong clinical rationale<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-development-timeline\" class=\"wp-block-heading\">Financial &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Expected Timeline<\/th><th>Strategic Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase III Completion<\/strong><\/td><td>2027-2028<\/td><td>Potential NDA filing in China and international markets<\/td><\/tr><tr><td><strong>Regulatory Submissions<\/strong><\/td><td>2028<\/td><td>Accelerated pathways possible given high unmet need in gastric cancer<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td>$300-600 million globally<\/td><td>Significant revenue contribution to Biokin&#8217;s growing oncology franchise<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>Moderate (leveraging existing platform)<\/td><td>Capital efficient development leveraging proven technology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial enrollment, development timelines, and commercial expectations for BL-M05D1. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260605_HWUU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260605_HWUU.\"><\/object><a id=\"wp-block-file--media-88c143be-7acb-4c77-9935-2135b36edc59\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260605_HWUU.pdf\">688506_20260605_HWUU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260605_HWUU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-88c143be-7acb-4c77-9935-2135b36edc59\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,62,857],"class_list":["post-67428","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M05D1, an innovative antibody drug conjugate (ADC) targeting Claudin18.2, in patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\/GEJC) who have received prior first-line therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67428\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M05D1, an innovative antibody drug conjugate (ADC) targeting Claudin18.2, in patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\/GEJC) who have received prior first-line therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67428\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:57:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:57:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67428#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67428\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer\",\"datePublished\":\"2026-06-05T05:57:45+00:00\",\"dateModified\":\"2026-06-05T05:57:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67428\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67428#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67428\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67428\",\"name\":\"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:57:45+00:00\",\"dateModified\":\"2026-06-05T05:57:46+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M05D1, an innovative antibody drug conjugate (ADC) targeting Claudin18.2, in patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\\\/GEJC) who have received prior first-line therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67428#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67428\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67428#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M05D1, an innovative antibody drug conjugate (ADC) targeting Claudin18.2, in patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\/GEJC) who have received prior first-line therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67428","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M05D1, an innovative antibody drug conjugate (ADC) targeting Claudin18.2, in patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\/GEJC) who have received prior first-line therapy.","og_url":"https:\/\/flcube.com\/?p=67428","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:57:45+00:00","article_modified_time":"2026-06-05T05:57:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67428#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67428"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer","datePublished":"2026-06-05T05:57:45+00:00","dateModified":"2026-06-05T05:57:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67428"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67428#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67428","url":"https:\/\/flcube.com\/?p=67428","name":"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:57:45+00:00","dateModified":"2026-06-05T05:57:46+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M05D1, an innovative antibody drug conjugate (ADC) targeting Claudin18.2, in patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC\/GEJC) who have received prior first-line therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67428#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67428"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67428#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67428"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67428\/revisions"}],"predecessor-version":[{"id":67431,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67428\/revisions\/67431"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}